Grufity logoGrufity logo

Gilead Sciences Inc Stock Research

GILD

78.56USD+0.75(+0.96%)Market Closed

Market Summary

USD78.56+0.75
Market Closed
0.96%

GILD Alerts

GILD Stock Price

GILD RSI Chart

GILD Valuation

Market Cap

98.0B

Price/Earnings (Trailing)

21.33

Price/Sales (Trailing)

3.59

EV/EBITDA

16.65

Price/Free Cashflow

11.74

GILD Price/Sales (Trailing)

GILD Profitability

EBT Margin

21.31%

Return on Equity

21.62%

Return on Assets

7.27%

Free Cashflow Yield

8.52%

GILD Fundamentals

GILD Revenue

Revenue (TTM)

27.3B

Revenue Y/Y

2%

Revenue Q/Q

4.93%

GILD Earnings

Earnings (TTM)

4.6B

Earnings Y/Y

329.32%

Earnings Q/Q

-8.33%

Price Action

52 Week Range

56.0689.29
(Low)(High)

Last 7 days

-1.6%

Last 30 days

-7.2%

Last 90 days

-7.3%

Trailing 12 Months

37.8%

GILD Financial Health

Current Ratio

1.29

Debt/Equity

1.19

Debt/Cashflow

0.36

GILD Investor Care

Dividend Yield

3.72%

Dividend/Share (TTM)

2.92

Buy Backs (1Y)

0.56%

Diluted EPS (TTM)

3.64

Peers (Alternatives to Gilead Sciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
124.2B
26.3B
-2.34% 1.62%
18.96
4.72
1.32% 11.18%
98.0B
27.3B
-7.18% 37.83%
21.33
3.59
-0.09% -26.23%
57.1B
19.3B
-7.28% -16.95%
6.83
2.97
4.29% -31.47%
38.1B
10.2B
-3.01% 25.82%
12.5
3.74
-7.36% 95.80%
MID-CAP
9.2B
1.5B
-6.54% 2.94%
59.61
6.19
31.34% 72.43%
3.1B
108.5M
-20.63% -31.77%
-9.51
28.59
122.90% -12.19%
2.2B
60.9M
-22.54% -46.32%
-7.52
35.66
17.51% 22.00%
1.9B
107.9M
7.80% 19.42%
-3.99
17.93
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-12.49% -50.70%
-4.44
10.58
-70.76% -603.77%
1.1B
7.0M
-19.12% 19.58%
-7.01
156.87
131.81% -45.39%
507.9M
96.3M
-13.43% -85.87%
-1.8
5.27
72.44% -32.79%
499.9M
2.0B
-38.13% -92.75%
-0.76
0.25
72.89% 62.27%
278.5M
111.3M
-41.20% -71.01%
-1.45
2.5
0.54% -7.86%
98.0M
107.0K
-22.42% -85.54%
-0.91
915.57
-88.00% -52.91%
26.6M
-
29.52% -80.89%
-0.33
3.21
0.51% -185.61%

Financials for Gilead Sciences

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.5%27,28127,13627,51527,47227,305
  S&GA Expenses7.0%5,6735,3035,2805,2745,246
Costs and Expenses-5.6%19,95121,13320,50720,24717,387
EBITDA21.5%7,0725,8196,8487,175-
EBITDA Margin20.9%0.26*0.21*0.25*0.26*-
Earnings Before Taxes28.0%5,8144,5425,5485,8628,278
EBT Margin27.3%0.21*0.17*0.20*0.21*-
Interest Expenses-1.3%9359479689821,001
Net Income37.7%4,5923,3344,1374,5156,225
Net Income Margin37.0%0.17*0.12*0.15*0.16*-
Free Cahsflow-7.4%8,3449,0079,4159,953-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.0%63,17162,55762,87063,08067,952
  Current Assets6.6%14,44313,55413,17512,62914,772
    Cash Equivalents15.2%5,4124,6994,7394,2965,338
  Inventory3.0%1,5071,4631,4941,4821,618
  Net PPE2.4%5,4755,3495,2995,2535,121
  Goodwill0%8,3148,3148,3148,3148,332
  Current Liabilities7.8%11,23710,4239,2208,55811,610
  Long Term Debt-3.8%25,22326,21626,20826,695-
    LT Debt, Current122.3%2,2701,0211,0251,516-
    LT Debt, Non Current0.0%22,95722,95325,19525,18325,179
Shareholder's Equity0.8%21,24021,08120,21519,91521,069
  Retained Earnings-0.4%15,68715,75615,11714,98616,324
  Additional Paid-In Capital6.2%5,5505,2265,0314,8674,661
Accumulated Depreciation-1,893----
Shares Outstanding-0.6%1,2471,2541,2541,2551,254
Minority Interest-29.2%-31.00-24.00-21.00-12.00-5.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-6.6%9,0729,71010,10010,61411,384
  Share Based Compensation2.4%637622625626635
Cashflow From Investing-4.1%-2,466-2,369-1,890-2,159-3,131
Cashflow From Financing5.7%-6,469-6,857-8,266-8,194-8,877
  Dividend Payments0.6%3,7093,6883,6593,6333,605
  Buy Backs95.8%1,396713668633546

Risks for GILD

What is the probability of a big loss on GILD?

51.9%


Probability that Gilead Sciences stock will be more than 20% underwater in next one year

0%


Probability that Gilead Sciences stock will be more than 30% underwater in next one year.

0%


Probability that Gilead Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GILD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.

Drawdowns

Returns for GILD

Cumulative Returns on GILD

8.5%


10-Year Cumulative Returns

1.3%


7-Year Cumulative Returns

5.4%


5-Year Cumulative Returns

6.7%


3-Year Cumulative Returns

What are the long-term rolling returns for GILD?

FIve years rolling returns for Gilead Sciences.

Annualized Returns

Which funds bought or sold GILD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
23.48
1,068,530
2,560,530
0.07%
2023-03-13
Claro Advisors LLC
reduced
-13.93
73,231
445,231
0.15%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-5.9
47,911,600
202,688,000
0.22%
2023-03-10
MATHER GROUP, LLC.
added
1.48
225,887
772,887
0.01%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-3.95
517,194
2,052,190
0.32%
2023-03-08
Capital Asset Advisory Services LLC
reduced
-14.87
113,665
621,665
0.05%
2023-03-06
OLD MISSION CAPITAL LLC
sold off
-100
-448,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-35.6
-1,266,000
10,922,000
0.06%
2023-03-03
TIAA, FSB
reduced
-76.76
-8,940,820
4,273,180
0.02%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
1,427,510
1,427,510
0.02%

1–10 of 47

Latest Funds Activity

Are funds buying GILD calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own GILD
No. of Funds

Gilead Sciences News

Best Stocks

Investment Partners LTD. reduces its stake in Gilead Sciences, Inc ....

Best Stocks,
2 hours ago

StockNews.com

Nasdaq

The Motley Fool

Investing News Network

Schedule 13G FIlings of Gilead Sciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
4.4%
54,602,952
SC 13G/A
Feb 13, 2023
capital world investors
5.5%
68,900,998
SC 13G
Feb 09, 2023
vanguard group inc
8.93%
112,038,324
SC 13G/A
Jan 31, 2023
blackrock inc.
10.5%
131,555,769
SC 13G/A
Jul 08, 2022
blackrock inc.
10.1%
126,932,693
SC 13G
Feb 11, 2022
capital research global investors
8.5%
107,156,981
SC 13G/A
Feb 10, 2022
vanguard group inc
8.43%
105,803,799
SC 13G/A
Feb 01, 2022
blackrock inc.
9.5%
118,961,206
SC 13G/A
Feb 16, 2021
capital research global investors
9.7%
121,672,399
SC 13G/A
Feb 16, 2021
capital research global investors
9.7%
121,672,399
SC 13G/A

GILD Fair Value

Gilead Sciences fair value in different scenarios

The table shows the Fair Value estimates for Gilead Sciences for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

21.64

-72.45%

27.25

-65.31%

43.63

-44.46%

72.06

-8.27%

87.89

11.88%
Current Inflation

20.58

-73.80%

25.77

-67.20%

40.40

-48.57%

63.07

-19.72%

76.28

-2.90%
Very High Inflation

19.20

-75.56%

23.86

-69.63%

36.36

-53.72%

52.66

-32.97%

62.94

-19.88%

Historical Gilead Sciences Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Gilead Sciences

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 09, 2023
3
Insider Trading
Mar 02, 2023
4
Insider Trading

Latest Insider Trading transactions for GILD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Parsey Merdad
sold
-483,893
78.99
-6,126
chief medical officer
2023-03-10
O'Day Daniel Patrick
acquired
-
-
30,288
chairman & ceo
2023-03-10
Parsey Merdad
sold (taxes)
-423,576
79.5
-5,328
chief medical officer
2023-03-10
Patterson Sandra
sold (taxes)
-63,679
79.5
-801
svp, controllership
2023-03-10
Patterson Sandra
acquired
-
-
2,921
svp, controllership
2023-03-10
Parsey Merdad
acquired
-
-
11,454
chief medical officer
2023-03-10
O'Day Daniel Patrick
sold (taxes)
-1,114,350
79.5
-14,017
chairman & ceo
2023-03-10
Dickinson Andrew D
sold (taxes)
-385,496
79.5
-4,849
chief financial officer
2023-03-10
Mercier Johanna
acquired
-
-
10,976
chief commercial officer
2023-03-10
Mercier Johanna
sold (taxes)
-406,722
79.5
-5,116
chief commercial officer

1–10 of 50

Daniel P. O'Day
14400
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Total revenues$ 27,281$ 27,305$ 24,689
Costs and expenses:   
Cost of goods sold5,6576,6014,572
Research and development expenses4,9774,6014,927
Acquired in-process research and development expenses9449395,968
In-process research and development impairment2,70000
Selling, general and administrative expenses5,6735,2465,151
Total costs and expenses19,95117,38720,618
Operating income7,3309,9184,071
Interest expense(935)(1,001)(984)
Other income (expense), net(581)(639)(1,418)
Income before income taxes5,8148,2781,669
Income tax expense(1,248)(2,077)(1,580)
Net income4,5666,20189
Net loss attributable to noncontrolling interest262434
Net income attributable to Gilead$ 4,592$ 6,225$ 123
Basic earnings per share attributable to Gilead (in dollars per share)$ 3.66$ 4.96$ 0.10
Shares used in basic earnings per share attributable to Gilead calculation (in shares)1,2551,2561,257
Diluted earnings per share attributable to Gilead (in dollars per share)$ 3.64$ 4.93$ 0.10
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)1,2621,2621,263
Product sales   
Revenues:   
Total revenues$ 26,982$ 27,008$ 24,355
Royalty, contract and other revenues   
Revenues:   
Total revenues$ 299$ 297$ 334

GILD Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 5,412$ 5,338
Short-term marketable debt securities9731,182
Accounts receivable, net4,7774,493
Inventories1,5071,618
Prepaid and other current assets1,7742,141
Total current assets14,44314,772
Property, plant and equipment, net5,4755,121
Long-term marketable debt securities1,2451,309
Intangible assets, net28,89433,455
Goodwill8,3148,332
Other long-term assets4,8004,963
Total assets63,17167,952
Current liabilities:  
Accounts payable905705
Accrued rebates3,4793,244
Other current liabilities4,5806,145
Current portion of long-term debt and other obligations, net2,2731,516
Total current liabilities11,23711,610
Long-term debt, net22,95725,179
Long-term income taxes payable3,9164,767
Deferred tax liability2,6734,356
Other long-term obligations1,179976
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding00
Common stock, par value $0.001 per share; 5,600 authorized; 1,247 and 1,254 shares issued and outstanding, respectively11
Additional paid-in capital5,5504,661
Accumulated other comprehensive income283
Retained earnings15,68716,324
Total Gilead stockholders’ equity21,24021,069
Noncontrolling interest(31)(5)
Total stockholders’ equity21,20921,064
Total liabilities and stockholders’ equity$ 63,171$ 67,952